<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00498979</url>
  </required_header>
  <id_info>
    <org_study_id>CASE3Y06</org_study_id>
    <secondary_id>P30CA043703</secondary_id>
    <nct_id>NCT00498979</nct_id>
  </id_info>
  <brief_title>Sodium Stibogluconate and IFNa-2b Followed By CDDP, VLB and DTIC Treating Pts.With Advanced Melanoma or Other Cancers</brief_title>
  <official_title>Phase I Evaluation of Sodium Stibogluconate in Combination With Interferon α-2b Followed by Cisplatin, Vinblastine and Dacarbazine for Patients With Melanoma or Malignancies Potentially Responsive to SSG and/or Interferons</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Case Comprehensive Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Case Comprehensive Cancer Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Sodium stibogluconate may stop the growth of tumor cells by blocking some of the
      enzymes needed for cell growth. Interferon alfa-2b may interfere with the growth of tumor
      cells and slow the growth of melanoma and other cancers. Drugs used in chemotherapy, such as
      cisplatin, vinblastine, and dacarbazine, work in different ways to stop the growth of tumor
      cells, either by killing the cells or by stopping them from dividing. Giving sodium
      stibogluconate and interferon alfa-2b together with combination chemotherapy may kill more
      tumor cells.

      PURPOSE: This phase I trial is studying the side effects and best dose of sodium
      stibogluconate when given together with interferon alfa-2b, cisplatin, vinblastine, and
      dacarbazine in treating patients with advanced melanoma or other cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:

      Primary

        -  To determine the safety of the combination of sodium stibogluconate and interferon
           alfa-2b with chemotherapy.

        -  To confirm the activity of sodium stibogluconate in augmenting cytokine effects.

      Secondary

        -  To quantify the effects of sodium stibogluconate on interferon alfa-2b induced gene
           modulation and signal transduction pathways by measuring the serum soluble gene
           products.

        -  To define the effectiveness of sodium stibogluconate in inhibiting the protein tyrosine
           phosphatases SHP-1 and SHP-2 assayed from peripheral blood leukocytes of patients
           receiving sodium stibogluconate in combination with interferon alfa-2b.

        -  To define the pharmacokinetics of sodium stibogluconate in serum at escalating doses.

        -  To assess clinical response to the combination of sodium stibogluconate and interferon
           alfa-2b as priming for combination chemotherapy.

      OUTLINE:

        -  Course 1: Patients receive sodium stibogluconate IV over 15 minutes on day 1 and days
           15-18; interferon alfa-2b subcutaneously (SC) on days 8-12 and 15-18; cisplatin IV over
           30-60 minutes and vinblastine IV on days 19 and 20; and dacarbazine. After a 2-week rest
           period, patients proceed to course 2.

        -  Course 2 and all subsequent courses: Patients receive sodium stibogluconate IV over 15
           minutes and interferon alfa-2b SC on days 1-4; cisplatin IV over 30-60 minutes and
           vinblastine IV on days 5 and 6; dacarbazine. Courses repeat every 4 weeks in the absence
           of disease progression or unacceptable toxicity.* NOTE: *Patients with stage IV disease
           who have no evidence of disease [NED} receive only 4 courses of therapy.

      Cohorts of 6 patients receive escalating doses of sodium stibogluconate until the maximum
      tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which
      dose-limiting toxicity occurs (i.e., no more than 1 patient at a given dose experiences DLT).

      Patients undergo blood sample collection periodically for immunological and pharmacokinetic
      studies. Samples are analyzed for serum soluble gene products and protein tyrosine
      phosphatase inhibition.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2007</start_date>
  <completion_date type="Actual">January 2012</completion_date>
  <primary_completion_date type="Actual">May 2010</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety of the combination of sodium stibogluconate and interferon alfa-2b with chemotherapy</measure>
    <time_frame>2 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Effects of sodium stibogluconate on interferon alfa-2b induced gene modulation and signal transduction pathways by measuring the serum soluble gene product</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effectiveness of sodium stibogluconate in inhibiting the protein tyrosine phosphatases SHP-1 and SHP-2 assayed from peripheral blood leukocytes</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of sodium stibogluconate in serum at escalating doses</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical response to the combination of sodium stibogluconate and interferon alfa-2b as priming for combination chemotherapy</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">22</enrollment>
  <condition>Stage IV Melanoma</condition>
  <arm_group>
    <arm_group_label>recombinant interferon alfa-2b</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>recombinant interferon alfa-2b</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>recombinant interferon alfa-2b</intervention_name>
    <description>recombinant interferon alfa-2b</description>
    <arm_group_label>recombinant interferon alfa-2b</arm_group_label>
    <other_name>IFN 2b</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cisplatin</intervention_name>
    <description>recombinant interferon alfa-2b</description>
    <arm_group_label>recombinant interferon alfa-2b</arm_group_label>
    <other_name>CDDP</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>sodium stibogluconate</intervention_name>
    <description>sodium stibogluconate</description>
    <arm_group_label>recombinant interferon alfa-2b</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>dacarbazine</intervention_name>
    <description>dacarbazine</description>
    <arm_group_label>recombinant interferon alfa-2b</arm_group_label>
    <other_name>DTIC</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>vinblastine</intervention_name>
    <description>vinblastine</description>
    <arm_group_label>recombinant interferon alfa-2b</arm_group_label>
    <other_name>VBL</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:

          -  Histologically confirmed melanoma or other malignancies

               -  Must be refractory or resistant to established treatments OR have metastatic
                  disease for which no effective therapy has been established

               -  Gliomas or controlled CNS metastasis allowed

                    -  A CT scan or MRI must confirm stable brain metastases within 28 days of
                       study entry

                    -  Patients with primary CNS malignancies refractory to other therapies are
                       eligible

          -  Malignancy potentially responsive to sodium stibogluconate and/or interferon alfa-2b
             and combination chemotherapy

          -  Patients must have measurable or evaluable disease

               -  Evaluable disease can include clinically or radiographically nonmeasurable tumor,
                  specific tumor markers, or stage IV patients with no evidence of disease (NED)

        PATIENT CHARACTERISTICS:

          -  Inclusion criteria:

               -  ECOG performance status 0-2

               -  Granulocytes &gt; 1,500/μl

               -  Platelets &gt; 100,000/μl

               -  Creatinine &lt; 1.5 x upper limit of normal (ULN)

               -  Bilirubin &lt; 1.5 x ULN

               -  AST and ALT &lt; 1.5 x ULN (unless due to hepatic metastases)

               -  Potassium ≤ 5.0 mmol/L

               -  Magnesium ≤ 2.4 mg/dL

               -  Creatinine clearance ≥ 60 cc/min

               -  Ejection fraction ≥ 50%

          -  Exclusion criteria:

               -  Pregnant or lactating women and fertile women or men unless surgically sterile or
                  using effective contraception

                    -  All female patients of childbearing potential or less than 1 year
                       postmenopausal must have a negative β-HCG pregnancy test at baseline and
                       practice a medically acceptable method of birth control (i.e., oral
                       contraceptives for at least 3 months, implantation of an intrauterine device
                       for at least 2 months, or barrier methods [e.g., vaginal diaphragm, vaginal
                       sponge, or condom with spermicidal jelly]) during and for 3 months after
                       study initiation

               -  History of atrial fibrillation, flutter, or other serious arrhythmia (excluding
                  asymptomatic atrial or ventricular premature complexes) in the past 24 months

               -  History of congestive heart failure currently requiring treatment; angina
                  pectoris; or other severe cardiovascular disease (i.e., New York Heart
                  Association class III or IV heart disease)

               -  Baseline ECG abnormalities suggestive of cardiac conduction delay (i.e., first
                  degree or greater atrio-ventricular block and/or complete or incomplete [QRS &gt;
                  120 ms] bundle branch block)

               -  Baseline ECG abnormalities suggestive of repolarization abnormalities (i.e., QTc
                  ≥ 0.48 sec)

               -  Culture positive acute infections requiring antibiotics within the past 14 days

                    -  Patients on long term suppressive antibiotic therapies are eligible

               -  Known to be positive for HBsAg

               -  Patients judged to not be psychologically prepared to understand informed consent
                  or comply with an investigational study

        PRIOR CONCURRENT THERAPY:

          -  Inclusion criteria:

               -  Prior interferon therapy is allowed if administered ≥ 4 months ago

               -  At least 3 weeks since prior major surgery, radiation therapy, or chemotherapy

          -  Exclusion criteria:

               -  No prior treatment with interferon, sodium stibogluconate, cisplatin,
                  vinblastine, or dacarbazine, except if given in an adjuvant setting

               -  Patients with a prior history of solid organ allografts or allogeneic bone marrow
                  transplant

               -  Patients taking the following medications will not be eligible:

                    -  Amiodarone (Cordarone)

                    -  Disopyramide (Norpace)

                    -  Dofetilide (Tikosyn)

                    -  Procainamide (Procanbid or Pronestyl)

                    -  Quinidine (Quinaglute)

                    -  Sotalol (Betapace)

                    -  Erythromycin

                    -  Azithromycin (Z-pack)

                    -  Clarithromycin (Biaxin)

                    -  Pentamidine (Pentacarinat)

                    -  Trimethoprim-sulfamethoxazole (Bactrim)

                    -  Bepridil (Vascor)

                    -  Phenothiazines (e.g., prochlorperazine [Compazine], promethazine
                       [Phenergan], or chlorpromazine [Thorazine])

                    -  Butyrophenones (e.g., Haloperidol [Haldol])

                    -  Risperidone (Risperdal)

                    -  Any other antipsychotic medication

                    -  Tricyclic or tetracyclic antidepressants (e.g., imipramine [Tofranil],
                       amitriptyline [Elavil], desipramine [Norpramin], or nortriptyline [Pamelor])

                    -  Monoamine oxidase inhibitors

                    -  High-dose methadone

                    -  Arsenic trioxide

                    -  Dolasetron (Anzemet)

                    -  Any herbal preparations

               -  Use of daily glucocorticoids except for physiological replacement
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ernest C. Borden, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Cleveland Clinic Taussig Institute, Case Comprehensive Cancer Center</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 10, 2007</study_first_submitted>
  <study_first_submitted_qc>July 10, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 11, 2007</study_first_posted>
  <last_update_submitted>September 29, 2015</last_update_submitted>
  <last_update_submitted_qc>September 29, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 30, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>stage IV melanoma</keyword>
  <keyword>adult anaplastic astrocytoma</keyword>
  <keyword>adult diffuse astrocytoma</keyword>
  <keyword>adult glioblastoma</keyword>
  <keyword>adult giant cell glioblastoma</keyword>
  <keyword>adult pilocytic astrocytoma</keyword>
  <keyword>adult brain stem glioma</keyword>
  <keyword>adult anaplastic ependymoma</keyword>
  <keyword>adult ependymoma</keyword>
  <keyword>adult myxopapillary ependymoma</keyword>
  <keyword>adult subependymoma</keyword>
  <keyword>adult anaplastic oligodendroglioma</keyword>
  <keyword>adult oligodendroglioma</keyword>
  <keyword>mixed gliomas</keyword>
  <keyword>recurrent adult brain tumor</keyword>
  <keyword>recurrent melanoma</keyword>
  <keyword>adult gliosarcoma</keyword>
  <keyword>adult subependymal giant cell astrocytoma</keyword>
  <keyword>adult pineal gland astrocytoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melanoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cisplatin</mesh_term>
    <mesh_term>Interferons</mesh_term>
    <mesh_term>Vinblastine</mesh_term>
    <mesh_term>Interferon-alpha</mesh_term>
    <mesh_term>Antimony Sodium Gluconate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

